Research Article

The Clinical and Economic Burden of Colorectal Anastomotic Leaks: Middle-Income Country Perspective

Ulysses Ribeiro Jr., 1 Daiane O. Tayar, 2 Rodrigo A. Ribeiro, 3 Priscila Andrade, 2 and Silvio M. Junqueira Jr. 2

1 Universidade de São Paulo Faculdade de Medicina, Brazil
2 Health Economics and Market Access Department, Johnson & Johnson Medical Devices Brazil, Brazil
3 HTAAnalyze Consulting, Brazil

Correspondence should be addressed to Daiane O. Tayar; dolive27@its.jnj.com

Received 9 October 2018; Revised 8 February 2019; Accepted 26 February 2019; Published 1 April 2019

Academic Editor: Valérie Bridoux

Copyright © 2019 Ulysses Ribeiro Jr. et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. Anastomotic leaks (AL) present a significant source of clinical and economic burden on patients undergoing colorectal surgeries. This study was aimed at evaluating the clinical and economic consequences of AL and its risk factors. Methods. A retrospective cohort study was conducted between 2012 and 2013 based on the billing information of 337 patients who underwent low anterior resection (LAR). The outcomes evaluated were the development of AL, use of antibiotics, 30-day readmission and mortality, and total hospital costs, including readmissions and length of stay (LOS). The risk factors for AL, as well as the relationship between AL and clinical outcomes, were analyzed using multivariable Poisson regression. Generalized linear models (GLM) were employed to evaluate the association between AL and continuous outcomes (LOS and costs). Results. AL was detected in 6.8% of the patients. Emergency surgery (aRR 2.56; 95% CI: 1.15–5.71, p = 0.021), blood transfusion (aRR 4.44; 95% CI: 1.86–10.64, p = 0.001), and cancer diagnosis (aRR 2.51; 95% CI: 1.27–4.98, p = 0.008) were found to be independent predictors of AL. Patients with AL showed higher antibiotic usage (aRR 1.69; 95% CI: 1.37–2.09, p < 0.001), 30-day readmission (aRR 3.34; 95% CI: 1.53–7.32, p = 0.001) and mortality (aRR 13.49; 95% CI: 4.10–44.35, p < 0.001), and longer LOS (39.6 days, as opposed to 7.5 days for patients without AL, p < 0.001). Total hospital costs amounted to R$210,105 for patients with AL in comparison with R$34,270 for patients without AL (p < 0.001). In multivariable GLM, the total hospital costs for AL patients were 4.66 (95% CI: 3.38–6.23, p < 0.001) times higher than those for patients without AL. Conclusions. AL leads to worse clinical outcomes and increases hospital costs by 4.66 times. The risk factors for AL were found to be emergency surgery, blood transfusion, and cancer diagnosis.

1. Introduction

An anastomotic leak (AL) is one of the most serious surgical complications that can develop following colorectal surgery [1]. In two recent systematic reviews, the AL rate varied from 4% to 9% [2, 3]. In the review that considered only low anterior resection (LAR) studies, the pooled overall rate of AL was found to be 8.88% [3]. Several risk factors for the occurrence of AL have been identified, including male sex, diabetes mellitus, use of tobacco, blood loss, perioperative transfusion, operative time, preoperative chemotherapy, previous abdominal surgery, and emergency surgery [3–17]. On the other hand, protective stoma could reduce the occurrence of AL or reduce the severity of the AL complication [16, 17], although its routine usage shows contradictory results [18].

AL has both clinical and economic consequences. Patients with AL have longer hospital length of stay (LOS), larger probability of infection, and higher intensive care unit (ICU) admission, hospital readmission, and mortality rates [7, 19]. All these factors, among the other morbidities associated with AL, incur increased costs in this subset of patients [6, 20, 21]. With regard to the economic outcomes, the cost impact of AL varies across different economies. Recent
studies have shown that the AL could increase total hospitalization costs by 0.5–1.9 times [6, 20].

The International Study Group of Rectal Cancer proposed a severity grading of AL following anterior rectal resections: grade A consists of the development of an AL treated conservatively, grade B requires invasive treatment but no surgery, and grade C requires reoperation [22].

Although there is information about the clinical and economic burden of AL in the literature, data continues to be scarce, especially in middle-income countries where financial burden poses greater challenges due to the resource constraints in such countries. The objective of this study was to evaluate the clinical and economic burden of AL in LAR in the Brazilian private healthcare system and investigate the risk factors for such outcomes.

2. Materials and Methods

2.1. Study Design and Dataset. The dataset of patients who consecutively underwent LAR between January 2012 and December 2013 was reviewed retrospectively. The administrative database of resource utilization from the Brazilian private healthcare system includes admissions, diagnoses, procedures, medications, transfusions, laboratory and imaging tests, the materials used during the patient’s hospitalization, and the cost of hospitalization. Approximately 12 million patients—which account for nearly 25% of the total patients in the Brazilian private healthcare system—are included in this administrative database. The tracking of the patients in this database is done based on their health insurance plan codes and not from specific hospitals, which provides reliable follow-up data in the short term, even in cases of readmission into different hospitals.

In this study, we excluded patients who did not meet the following eligibility criteria: available age, gender, surgical approach (open or laparoscopic), and the International Classification of Diseases (ICD) code. Moreover, the LAR must have been performed no more than 3 days after the hospital admission.

2.2. Study Variables. The following variables were evaluated for each patient: age, gender, preoperative chemoradiation, ICD code for admission related to the surgery, surgical approach, extent of surgery (multivisceral resection or standard LAR), protective stoma, timing of the procedure (emergency versus elective surgery), in-hospital mortality, hospital LOS, ICU admission, 30-day readmission, antibiotic usage, perioperative blood transfusion, occurrence of AL, and hospitalization costs.

Antibiotic usage was defined as postoperative exposure to a nonprophylactic antibiotic for over 7 days within 30 days of the index surgery, while perioperative transfusion was defined as the use of red cell concentrate within 30 days of the index surgery. AL was considered to be the combination of three conditions: (1) a reoperation or image-guided percutaneous drainage within 30 days of the index surgery; (2) a sign of a clinical AL investigation with at least one postoperative imaging study, such as computed tomography (CT) scan, abdominal X-ray, or other abdominal exams with intravenous contrast; and (3) a sign of a clinical infection investigation with a blood culture exam within 30 days of the index surgery. Only the patients classified as B and C, according to the International Study Group of Rectal Cancer, were included in the AL group [22].

The economic outcomes considered the total hospitalization costs, including 30-day readmissions. These included the cost of materials, pharmacy, transfusion, laboratory and imaging tests, procedures, therapies, inpatient care, and intensive care.

The clinical outcomes were evaluated in terms of both the index surgery admission and any readmission within 30 days. The outcomes that were evaluated and computed in the analysis include in-hospital mortality, hospital LOS, ICU admission, 30-day readmission, antibiotic usage, and AL.

2.3. Statistical Analysis. Only cases with no missing values were included in the analysis. Continuous variables were evaluated using Student’s t-test, and categorical variables were evaluated using the chi-square test or Fisher’s exact test. The variables with a p value < 0.1 were initially considered for the multivariate analysis. Multivariable Poisson regression analysis was used and presented as a risk ratio (RR) with 95% confidence interval (CI) to determine the factors associated with AL. In order to evaluate costs and LOS, a generalized linear model (GLM) was employed, since it is the preferred approach for multivariate analysis of cost data with gamma distribution [20]. All analyses were two-sided, and a p value < 0.05 was considered statistically significant. The statistical analysis was performed using the SPSS (Statistical Package for Social Sciences, version 20.0, Chicago, IL, USA).

3. Results

Among the 1,321 potentially eligible patients, 337 fulfilled the eligibility criteria and were included in the analysis (Figure 1). Throughout the index admission, 5.3% of patients fulfilled our criteria for the presence of AL, while considering 30-day readmissions, 1.5% of patients were added, totaling up to 6.8% incidence of AL. Of these, 23 patients developed AL: 1 patient required image-guided percutaneous drainage and 22 required reoperation.

The demographics and perioperative patients’ data are presented in Table 1. The mean age was 53.0 ± 16.2 in patients with AL and 51.6 ± 15.4 in patients without AL (p = 0.67). The proportion of patients with cancer was higher in patients who developed AL (51.3%) in comparison with those without AL (27.4%) (p = 0.016). There was no difference in the use of chemotherapy and radiotherapy among the groups (p = 1.00 for both comparisons).

3.1. Risk Factors for AL. Table 2 presents an association between possible predictors and AL. Factors such as male sex, cancer diagnosis, emergency surgery, protective stoma, and perioperative blood transfusion increased the incidence of AL in the univariate analysis. No significant differences were found for the procedure extension and surgical approach. When included in the multivariable regression
analysis, cancer diagnosis, emergency surgery, and perioperative blood transfusion maintained their significance.

3.2 Impact of AL on Clinical Outcomes. Some of the major clinical outcomes are presented in Table 3. Patients with AL showed increased antibiotic usage and higher incidence of readmission and mortality during the follow-up. LOS was also higher in patients with AL (39.6 ± 48.6 days as opposed to 7.5 ± 6.7 days, p < 0.001). In the multivariate analysis, including the significant variables (p < 0.05), all the analyzed outcomes remained significantly associated with AL. The largest impact of AL was on the mortality rate, which was found to be 13.49 times higher in AL patients than in patients without AL in the analysis adjusted for age, gender, cancer diagnosis, and timing of surgery (p < 0.001).

3.3 Impact of AL on Economic Outcomes. The economic outcomes of the patients are displayed in Table 4, including data for the whole cohort according to the presence of perioperative AL. The total hospital costs and the index admission costs were found to be greater for patients with AL as compared to patients without AL. The average incremental cost attributable to AL was BRL (Brazilian reais) 170,904 when only index admissions were considered and BRL 175,835 when total hospitalization costs were considered. Readmission costs tended to increase in patients with AL as compared to patients without AL (BRL 6,988 ± 12,965, as opposed to BRL 2,057 ± 10,431, respectively). The increase in costs is attributable to higher service needs. There was not any patient transfer to higher-level medical centers.

In the GLM analysis, the total costs for patients with AL were 6 times higher than those for patients without AL (univariate GLM model coefficient = 6.13; 95% CI:...

Table 1: Demographics and perioperative information of the study patients.

| Variable                  | With AL (N = 23) | Without AL (N = 314) | p value |
|---------------------------|-----------------|----------------------|---------|
| Male gender               |                 |                      | 0.049   |
| Age (years)               | 53.0 ± 16.2     | 51.6 ± 15.4          | 0.670   |
| ICD code                  |                 |                      | 0.093   |
| Gastrointestinal cancers  |                 |                      |         |
| Other cancers³            |                 |                      |         |
| Endometriosis             |                 |                      |         |
| Diverticular disease      |                 |                      |         |
| Other²                    |                 |                      |         |
| Chemotherapy              |                 |                      |         |
| Radiotherapy              |                 |                      |         |
| Emergency surgery         |                 |                      |         |
| Multivisceral resection   |                 |                      |         |
| Laparoscopic surgery      |                 |                      |         |
| Protective stoma¹         |                 |                      |         |
| ICU admission             |                 |                      |         |
| Blood transfusion         |                 |                      |         |

The sample is comprised of 337 patients. Data is presented as the number of patients (%) except for age, which is expressed as mean ± standard deviation. ICU: intensive care unit; ICD: International Classification of Diseases. ¹There were 11 cases of cancer in other localizations (3 cervical cancers, 5 ovarian cancers, 2 prostate cancers, and 1 uterine cancer) and 2 unspecified cancer codes. ²An unspecified diagnosis such as the acute abdomen, bowel abscess, inflammatory bowel disease, bowel motility disorders, abdominal pain, hemorrhage, intra-abdominal mass, benign tumors, intestinal obstruction, peritonitis, and bowel volvulus.
In the construction of a multivariable GLM model that evaluated the total costs, other possible predictors for costs were considered. Multivisceral resection had a $p$ value = 0.42. Therefore, it did not enter the multivariable model. The variables selected for GLM were AL, age, gender, cancer diagnosis, timing of surgery, protective stoma, and surgical approach. The coefficients in the multivariable GLM analysis are presented in Table 5. After adjustment for possible confounders, the model showed 4.66 times higher total costs (95% CI, 3.48–6.23, $p < 0.001$) for AL patients than for patients without AL.

Table 2: Univariate and multivariable analyses of the possible predictors of AL.

| Variables                      | AL incidence | Crude RR (95% CI) | $p$ | Adjusted RR (95% CI) | $p$ |
|--------------------------------|--------------|-------------------|-----|----------------------|-----|
| Gender                         |              |                   |     |                      |     |
| Male                           | 14 (10.2)    | 2.27 (1.01–5.09)  | 0.049 | 1.72 (0.82–3.62)      | 0.148 |
| Female                         | 9 (4.5)      |                   |     |                      |     |
| Surgery timing                 |              |                   |     |                      |     |
| Emergency                      | 9 (15.8)     | 3.16 (1.44–6.94)  | 0.007 | 2.56 (1.15–5.71)      | 0.021 |
| Elective                       | 14 (5.0)     |                   |     |                      |     |
| Procedure extension            |              |                   |     |                      |     |
| Multivisceral resection        | 9 (8.0)      | 1.29 (0.58–2.89)  | 0.647 | —                    | —   |
| Standard LAR                   | 14 (6.2)     |                   |     |                      |     |
| Surgical approach              |              |                   |     |                      |     |
| Open                           | 18 (8.4)     | 2.07 (0.79–5.43)  | 0.178 | —                    | —   |
| Laparoscopic                   | 5 (4.1)      |                   |     |                      |     |
| Blood transfusion              |              |                   |     |                      |     |
| Yes                            | 13 (22.8)    | 6.38 (2.94–13.84) | <0.001 | 4.44 (1.85–10.63)     | 0.001 |
| No                             | 10 (3.6)     |                   |     |                      |     |
| Protective stoma               |              |                   |     |                      |     |
| Yes                            | 11 (19.6)    | 4.59 (2.13–9.89)  | <0.001 | 1.88 (0.74–4.80)      | 0.185 |
| No                             | 12 (4.3)     |                   |     |                      |     |
| Cancer diagnosis               |              |                   |     |                      |     |
| Yes                            | 12 (12.2)    | 2.66 (1.22–5.83)  | 0.017 | 2.51 (1.27–4.98)      | 0.008 |
| No                             | 11 (4.6)     |                   |     |                      |     |

Incidence is presented as $N$ (%). $p$ value was calculated by Fisher’s exact test in the crude analysis with Poisson regression in the multivariable analysis. The multivariable Poisson regression included variables with $p < 0.10$ in univariate analysis: gender, surgery timing, cancer, and need for blood transfusion. AL: anastomotic leak; CI: confidence interval; RR: relative risk.

Table 3: Clinical outcomes according to the presence of AL.

| Outcomes                  | With AL ($N = 23$) | Without AL ($N = 314$) | Crude RR (95% CI) | $p$     | Adjusted RR (95% CI) | $p$     |
|---------------------------|---------------------|-------------------------|-------------------|---------|----------------------|---------|
| Use of antibiotics        | 20 (87.0)           | 146 (46.5)              | 1.87 (1.54–2.28)  | <0.001  | 1.69 (1.37–2.09)     | <0.001  |
| Mortality                 | 5 (21.7)            | 4 (1.3)                 | 17.06 (4.91–59.25)| <0.001  | 13.49 (4.10–44.35)   | <0.001  |
| Readmission               | 6 (26.1)            | 26 (8.3)                | 3.15 (1.44–6.87)  | 0.014   | 3.34 (1.53–7.32)     | 0.003   |
| LOS                       | 39.6 ± 48.6         | 7.5 ± 6.7               | 5.20 (3.91–6.90)  | <0.001  | 4.42 (3.38–5.78)     | <0.001  |

Data is presented as $N$ (%), except for LOS, which is presented as mean ± standard deviation. Crude RR was calculated from contingency tables, except for the LOS, where a generalized linear model (GLM) was used (both in the crude and in the adjusted RR). Adjusted RR (except for LOS) was calculated using Poisson regression. Adjusted analyses included age, gender, cancer status, and timing of surgery as covariables (except for LOS, where gender was omitted in order to achieve model convergence). $p$ values were obtained by Fisher’s exact test and Poisson regression for all variables except for LOS, which was calculated with GLM. AL: anastomotic leak; CI: confidence interval; LOS: length of stay; RR: relative risk.

Table 4: Cost outcomes (Brazilian R$ or BRL) for the whole cohort according to the presence of AL.

| Time period | Whole cohort | With AL ($N = 23$) | Without AL ($N = 314$) | $p$ value |
|-------------|--------------|---------------------|-------------------------|-----------|
| Index admission | 43,878 ± 83,265 | 203,117 ± 242,601 | 32,213 ± 36,136 | 0.003     |
| Readmissions | 2,393 ± 10,673 | 6,988 ± 12,965 | 2,057 ± 10,431 | 0.087     |
| Total costs | 46,271 ± 83,675 | 210,105 ± 238,091 | 34,270 ± 37,613 | 0.002     |

Values are expressed as mean ± standard deviation. AL: anastomotic leak; IQR: interquartile range. $p$ value was calculated using Student’s $t$-test.
4. Discussion

AL is a significant cause of postoperative morbidity following colorectal surgery. In this study, we investigated clinical and economic consequences as well as possible predictors for the occurrence of AL with a cohort of patients undergoing LAR for colorectal diseases from a middle-income country, Brazil.

The present study showed that AL, after adjustment for possible confounders, increases the risk of antibiotic usage by approximately 70%, the probability of hospital readmission by three times, and hospital LOS by 4.4 times. Additionally, it has a huge impact on mortality, with a relative risk (RR) of 13.46 (95% CI: 4.10–44.35, *p* < 0.001). It also increases the risk of antibiotic usage by approximately 70%, the probability of hospital readmission by 4.4 times, and hospital LOS by 4.4 times. Univariate analysis showed that AL is highly associated with the total costs in the crude analysis was over 6 times higher in the AL group; in the multivariable GLM analysis, which accounted for possible confounders, the association was lower but still significant, with 4.7 times higher total costs (including index admission and 30-day readmission). This can be very challenging in hospitals that are reimbursed by diagnosis-related groups (DRG) or other types of flat-fee agreements, as a high incidence of AL generates substantial expenditure. On the other hand, the reimbursement is fee for the service, healthcare plans would be financially penalized in case of the occurrence of higher-than-expected AL incidence.

Table 5: GLM for total costs (index admission plus readmissions).

| Variable          | Crude estimate | 95% CI      | *p*    | Multivariable estimate | 95% CI      | *p*    |
|-------------------|----------------|-------------|--------|------------------------|-------------|--------|
| Anastomotic leak  | 6.13           | 4.49–8.35   | <0.001 | 4.66                   | 3.48–6.23   | <0.001 |
| Emergency surgery | 1.81           | 1.40–2.32   | <0.001 | 1.25                   | 1.01–1.54   | 0.038  |
| Age               | 1.02           | 1.01–1.02   | <0.001 | 1.01                   | 1.01–1.02   | <0.001 |
| Male gender       | 1.47           | 1.21–1.78   | <0.001 | 0.87                   | 0.74–1.01   | 0.070  |
| Laparoscopy       | 0.683          | 0.56–0.83   | <0.001 | 1.29                   | 1.11–1.52   | 0.001  |
| Cancer            | 1.54           | 1.25–1.90   | <0.001 | 1.29                   | 1.09–1.52   | 0.002  |
| Protective stoma  | 3.15           | 2.50–3.97   | <0.001 | 1.91                   | 1.54–2.36   | <0.001 |
| Intercept         | —              | —           | —      | 14,221                 | 10,739–18,832| <0.001 |

Multivariable estimates were adjusted for all the variables presented in this table.

Some limitations of our study must be acknowledged. The dataset used for all the analyses was based on the patients’ administrative information. This approach carries the risk of bias of other retrospective studies as well as the problems associated with the lack of individual clinical patient information, such as the type of Anastomosis and tumor distance from the anal verge. A better adjustment in the multivariable analysis could possibly be achieved with more clinical variables, and the definition of AL could be more precise if data from patients’ charts was available, for instance. Also, in our multivariable analysis, especially the ones regarding mortality and AL incidence, the number of events was small, and a more robust analysis would demand larger events per covariable proportion. Furthermore, our present study may have underestimated the AL rate. A study conducted with the Swedish Colorectal Cancer Registry...
showed that the false-negative rate could constitute almost 30% of the AL diagnosis [25]. The occurrence of AL in our study was evaluated only within the 30-day postoperative period, while a study conducted by the Dutch Snapshot Research Group showed that the AL rate could increase by almost 50% beyond 30 days after the surgery [26]. However, considering the incidence of AL grades B and C, which is in line with the other reports in the literature, we believe the risk of AL misclassification to be low. Therefore, the analysis of costs associated with AL is robust, especially the univariate analysis, which does not depend on the deeper verification of possible confounders. Another limitation of our study is the exclusion of over 75% of the original sample secondary to our eligibility criteria, which poses a risk of selection bias. In this regard, it calls attention to the large number of patients with an ICD code of endometriosis. Although this disease does not usually present as an important reason for colorectal surgeries, its rate can be substantial, as seen in a recent French analysis from a national colorectal surgery database [27]. One possible explanation for the high incidence of endometriosis in our sample is that considering that the disease is not frequently associated with colorectal surgeries, the physician might have used this ICD code more accurately than that for other diseases to get approval from the health insurance plans. Since our inclusion criteria required the presence of an ICD code, the incidence of endometriosis in the sample might be secondary to better noting of this information by physicians. Finally, the occurrence of AL and mortality was found to be quite low, and some of this information by physicians. Finally, the occurrence of endometriosis in our sample might be secondary to better noting of this information by physicians. Finally, the occurrence of AL leading to a heavy burden in LAR procedures from both the clinical and economic perspectives, increasing the hospital costs by 4.66 times. The risk factors identified for the development of AL were emergency surgery, blood transfusion, and cancer diagnosis.

Data Availability

The dataset is available from the ResearchGate repository (DOI: 10.13140/RG.2.2.13952.69128). Further information is available from the corresponding author on request.

Disclosure

This study was presented at the 67th Brazilian Congress of Coloproctology 2018 (Gramado, Brazil).

Conflicts of Interest

Daiane Oliveira Tayar, Priscila Andrade, and Silvio Mauro Junqueira Jr. are employees of Johnson & Johnson Medical Devices Brazil. Rodrigo Antonini Ribeiro received a research grant from Johnson & Johnson Medical Devices Brazil to access the database and conduct the statistical analyses included in this paper. Ulysses Ribeiro Jr. declares that no competing financial interests exist regarding this manuscript.

Authors’ Contributions

Ulysses Ribeiro Jr. had a substantial contribution to the conception and design of the work and to the interpretation of data, drafted the article and revised it critically for important intellectual content, had the final approval of the version to be published, is accountable for all aspects of the work, and ensured that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. He is accountable for the parts of the work done by him and able to identify which coauthors are responsible for other parts of the work. He is confident in the integrity of the contributions of his coauthors. Daiane O. Tayar had a substantial contribution to the conception and design of the work, drafted the article and revised it critically for important intellectual content, had the final approval of the version to be published, is accountable for all aspects of the work, and ensured that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. She is accountable for the parts of the work done by her and able to identify the coauthors responsible for other parts of the work. She is confident in the integrity of the contributions of her coauthors. Rodrigo A. Ribeiro had a substantial contribution to the acquisition, analysis, and interpretation of the data for the work, drafted the article, had the final approval of the version to be published, had the accountability for all aspects of the work, and ensured that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. He is accountable for the parts of the work done by him and able to identify the coauthors responsible for other parts of the work. He is confident in the integrity of the contributions of his coauthors. Priscila Andrade had a substantial contribution to the conception and design of the work, drafted the article, had the final approval of the version to be published, is accountable for all aspects of the work, and ensured that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. She is accountable for the parts of the work done by her and able to identify the coauthors responsible for other parts of the work. She is confident in the integrity of the contributions of her coauthors. Silvio M. Junqueira Jr. had a substantial contribution to the conception and design of the work, critically revised the article for important intellectual content, had the final approval of the version to be published, is accountable for all aspects of the work, and ensured that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. He is accountable for the parts of the work done by him and able to identify the coauthors responsible for the other parts of the work. He is confident in the integrity of the contributions of his coauthors.

Acknowledgments

This study and the development of this manuscript were supported by Johnson & Johnson Medical Devices Brazil.
References

[1] T. Akiyoshi, M. Ueno, Y. Fukunaga et al., "Incidence of and risk factors for anastomotic leakage after laparoscopic anterior resection with intracorporeal rectal transection and double-stapling technique anastomosis for rectal cancer," *American Journal of Surgery*, vol. 202, no. 3, pp. 259–264, 2011.

[2] Z. J. Cong, L. H. Hu, Z. Q. Bian et al., "Systematic review of anastomotic leakage rate according to an international grading system following anterior resection for rectal cancer," *PloS One*, vol. 8, no. 9, article e75519, 2013.

[3] A. Schiff, B. L. Brady, S. K. Ghosh, S. Roy, C. Ruetsch, and E. Fegelman, "Estimated rate of post-operative anastomotic leak following colorectal resection surgery: a systematic review," *Journal of Surgery and Surgical Research*, vol. 2, pp. 66–67, 2015.

[4] K. Kawada and Y. Sakai, "Preoperative, intraoperative and postoperative risk factors for anastomotic leakage after laparoscopic low anterior resection with double stapling technique anastomosis," *World Journal of Gastroenterology*, vol. 22, no. 25, pp. 5718–5727, 2016.

[5] K. Kawada, S. Hasegawa, K. Hida et al., "Risk factors for anastomotic leakage after laparoscopic low anterior resection with DST anastomosis," *Surgical Endoscopy*, vol. 28, no. 10, pp. 2988–2995, 2014.

[6] S. Q. Ashraf, E. M. Burns, A. Jani et al., "The economic impact of anastomotic leakage after anterior resections in English NHS hospitals: are we adequately remunerating them?", *Colorectal Disease*, vol. 15, no. 4, pp. e190–e198, 2013.

[7] P. M. Krarup, A. Nordholm-Carstensen, L. N. Jorgensen, and H. Harling, "Association of comorbidity with anastomotic leak, 30-day mortality, and length of stay in elective surgery for colonic cancer: a nationwide cohort study," *Diseases of the Colon & Rectum*, vol. 58, no. 7, pp. 668–676, 2015.

[8] E. García-Granero, F. Navarro, C. Cerdán Santacruz et al., "Individual surgeon is an independent risk factor for leak after double-stapled colorectal anastomosis: an institutional analysis of 800 patients," *Surgery*, vol. 162, no. 5, pp. 1006–1016, 2017.

[9] S. H. Jung, C. S. Yu, P. W. Choi et al., "Risk factors and oncologic impact of anastomotic leakage after rectal cancer surgery," *Diseases of the Colon & Rectum*, vol. 51, no. 6, pp. 902–908, 2008.

[10] P. Matthiesen, O. Hallbook, M. Andersson, J. Rutegård, and R. Sjodahl, "Risk factors for anastomotic leakage after anterior resection of the rectum," *Colorectal Disease*, vol. 6, no. 6, pp. 462–469, 2004.

[11] J. S. Park, G. S. Choi, S. H. Kim et al., "Multicenter analysis of risk factors for anastomotic leakage after laparoscopic rectal cancer excision: the Korean laparoscopic colorectal surgery study group," *Annals of Surgery*, vol. 257, no. 4, pp. 665–671, 2013.

[12] V. C. Nikolian, N. S. Kamdar, S. E. Regenbogen et al., "Anastomotic leak after colorectal resection: a population-based study of risk factors and hospital variation," *Surgery*, vol. 161, no. 6, pp. 1619–1627, 2017.

[13] H. Caulfield and N. H. Hyman, "Anastomotic leak after low anterior resection: a spectrum of clinical entities," *JAMA Surgery*, vol. 148, no. 2, pp. 177–182, 2013.

[14] S. Shinji, Y. Ueda, T. Yamada et al., "Male sex and history of ischemic heart disease are major risk factors for anastomotic leakage after laparoscopic anterior resection in patients with rectal cancer," *BMC Gastroenterology*, vol. 18, no. 1, p. 117, 2018.

[15] J. A. Yun, Y. B. Cho, Y. A. Park et al., "Clinical manifestations and risk factors of anastomotic leakage after low anterior resection for rectal cancer," *ANZ Journal of Surgery*, vol. 87, no. 11, pp. 908–914, 2017.

[16] W. Zhang, Z. Lou, Q. Liu et al., "Multicenter analysis of risk factors for anastomotic leakage after middle and low rectal cancer resection without diverting stoma: a retrospective study of 319 consecutive patients," *International Journal of Colorectal Disease*, vol. 32, no. 10, pp. 1431–1437, 2017.

[17] M. A. Frouws, H. S. Snijders, S. H. Malm et al., "Clinical relevance of a grading system for anastomotic leakage after low anterior resection: analysis from a national cohort database," *Diseases of the Colon & Rectum*, vol. 60, no. 7, pp. 706–713, 2017.

[18] A. Emmanuel, E. Chohda, C. Lapa, A. Miles, A. Haji, and J. Ellul, "Defunctioning stomas result in significantly more short-term complications following low anterior resection for rectal cancer," *World Journal of Surgery*, vol. 42, no. 11, pp. 3755–3764, 2018.

[19] C. H. Richards, V. Campbell, C. Ho, J. Hayes, T. Elliott, and M. Thompson-Fawcett, "Smoking is a major risk factor for anastomotic leak in patients undergoing low anterior resection," *Colorectal Disease*, vol. 14, no. 5, pp. 628–633, 2012.

[20] J. Hammond, S. Lim, Y. Wan, X. Gao, and A. Patkar, "The burden of gastrointestinal anastomotic leaks: an evaluation of clinical and economic outcomes," *Journal of Gastrointestinal Surgery*, vol. 18, no. 6, pp. 1176–1185, 2014.

[21] F. E. Turrentine, C. E. Denlinger, V. B. Simpson et al., "Morbidity, mortality, cost, and survival estimates of gastrointestinal anastomotic leaks," *Journal of the American College of Surgeons*, vol. 220, no. 2, pp. 195–206, 2015.

[22] N. N. Rahbari, J. Weitz, W. Hohenberger et al., "Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer," *Surgery*, vol. 147, no. 3, pp. 339–351, 2010.

[23] P. Boström, M. M. Haapamäki, J. Rutegård, P. Matthiesen, and M. Rutegård, "Population-based cohort study of the impact on postoperative mortality of anastomotic leakage after anterior resection for rectal cancer," *BJS Open*, vol. 3, no. 1, pp. 106–111, 2019.

[24] M. Drummond, M. Barbieri, J. Cook et al., "Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report," *Value in Health*, vol. 12, no. 4, pp. 409–418, 2009.

[25] M. Rutegård, D. Kverneng Hultberg, E. Anengete, and M. L. Lydrup, "Substantial underreporting of anastomotic leakage after anterior resection for rectal cancer in the Swedish Colorectal Cancer Registry," *Acta Oncologica*, vol. 56, no. 12, pp. 1741–1745, 2017.

[26] W. A. A. Borstlap, E. Westerduin, T. S. Aukema, W. A. Bemelman, P. J. Tanis, and Dutch Snapshot Research Group, "Anastomotic leakage and chronic presacral sinus formation after low anterior resection: results from a large cross-sectional study," *Annals of Surgery*, vol. 266, no. 5, pp. 870–877, 2017.

[27] H. Roman and FRIENDS group (French colorectal Infiltrating ENDometriosis Study group), "A national snapshot of the surgical management of deep infiltrating endometriosis of the rectum and colon in France in 2015: a multicenter series of 1135 cases," *Journal of Gynecology Obstetrics and Human Reproduction*, vol. 46, no. 2, pp. 159–165, 2017.
